Exclusive Summary

• First-in-class & Best-in-class Potential: UB688 is the world's first IL-1α/β bispecific antibody to enter clinical trials for endometriosis (EM), while also demonstrating best-in-class potential for hidradenitis suppurativa (HS).
• Highly Differentiated MoA: It efficiently targets both IL-1α and IL-1β without binding to the endogenous IL-1 receptor antagonist (IL-1Ra), thereby preserving innate regulatory mechanisms and yielding superior anti-inflammatory efficacy compared to main competitor Lutikizumab.
• Outstanding Patient Compliance: Utilizing a platform Fc engineering design, the drug significantly extends its half-life, allowing for convenient subcutaneous dosing of at least once every 8 weeks (≥Q8W), drastically reducing the burden on chronic disease patients.
• Explosive Market Potential: The pipeline brilliantly addresses two multi-billion dollar markets with massive unmet needs: Women's Health (a non-hormonal blue ocean for EM) and Autoimmune Dermatology (the rapidly growing HS market).
• High Attractiveness for Global Partnership: Backed by solid superior preclinical data, patent-protectable dual-targeting design, and a patient-friendly dosing regimen, UB688 is perfectly positioned for out-licensing to MNCs looking to secure a strategic blockbuster asset in immunology or women's health.

Asset Materials

Contact Us for Full Materials